Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In ASCEND and ELEVATE treatment-naive studies, acalabrutinib monotherapy combined with obinutuzumab demonstrated improved efficacy and an acceptable safety profile (CLL & Drugs/Treatments)
Egyed et al. 2022 Future Oncology 18: 755-769
These data support the use of acalabrutinib in combination with obinutuzumab or alone as a new treatment option for patients with treatment-naive symptomatic chronic lymphocytic leukaemia.
see also:
[B-lymphocyte antigen CD20 (CD20) antibodies + Bruton's tyrosine kinase (BTK) inhibitors & Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL…